Abstract

Simple SummaryThe etiologic role of biliary reflux in hypopharyngeal cancer is supported by clinical data. Although, reflux episodes often occur at pH 4.0, they can also occur at weakly acidic pH (5.5–6.0). The carcinogenic effect of bile at strongly acidic pH (pH 3.0) was recently documented in vivo. Here, we provide novel in vivo evidence that a weakly acidic pH of 5.5, similarly to a strongly acidic pH of 3.0, increases the risk of bile-related hypopharyngeal neoplasia. We document that chronic exposure of hypopharyngeal mucosa to bile at pH 5.5 promotes premalignant lesions with DNA damage, NF-κB activation, and deregulated mRNA and miRNA phenotypes, including Bcl-2 and miR-451a. The oncogenic effects of bile over a wider pH range suggests that antacid therapy may be insufficient to fully modify the effects of a bile induced oncogenic effect.Background: There is recent in vivo discovery documenting the carcinogenic effect of bile at strongly acidic pH 3.0 in hypopharynx, while in vitro data demonstrate that weakly acidic bile (pH 5.5) has a similar oncogenic effect. Because esophageal refluxate often occurs at pH > 4.0, here we aim to determine whether weakly acidic bile is also carcinogenic in vivo. Methods: Using 32 wild-type mice C57B16J, we performed topical application of conjugated primary bile acids with or without unconjugated secondary bile acid, deoxycholic acid (DCA), at pH 5.5 and controls, to hypopharyngeal mucosa (HM) twice per day, for 15 weeks. Results: Chronic exposure of HM to weakly acidic bile, promotes premalignant lesions with microinvasion, preceded by significant DNA/RNA oxidative damage, γH2AX (double strand breaks), NF-κB and p53 expression, overexpression of Bcl-2, and elevated Tnf and Il6 mRNAs, compared to controls. Weakly acidic bile, without DCA, upregulates the “oncomirs”, miR-21 and miR-155. The presence of DCA promotes Egfr, Wnt5a, and Rela overexpression, and a significant downregulation of “tumor suppressor” miR-451a. Conclusion: Weakly acidic pH increases the risk of bile-related hypopharyngeal neoplasia. The oncogenic properties of biliary esophageal reflux on the epithelium of the upper aerodigestive tract may not be fully modified when antacid therapy is applied. We believe that due to bile content, alternative therapeutic strategies using specific inhibitors of relevant molecular pathways or receptors may be considered in patients with refractory GERD.

Highlights

  • Laryngopharyngeal tumors are mainly squamous cell carcinomas and are among the most aggressive and devastating cancers

  • To investigate whether chronic exposure of hypopharyngeal mucosa (HM) to weakly acidic bile can cause histopathologic alterations that support premalignant or malignant changes, we used histologic staining and performed histologic evaluation based on previously established criteria [43,44,45]

  • Bile treatment included a mixture of conjugated primary bile acids (10 mmol/L in buffered saline) (~4 μmol per day) with and without unconjugated secondary bile acid deoxycholic acid (0.28 mmol/L) (~0.1 μmol per day) (DCA; Alfa Aesar®, Tewksbury, MA, USA) at concentrations previously described in GERD patients [5,7,37], at a weakly acidic pH of 5.5, adjusted with 1 M HCl

Read more

Summary

Introduction

Laryngopharyngeal tumors are mainly squamous cell carcinomas and are among the most aggressive and devastating cancers. Using an in vivo mouse model, we recently demonstrated that conjugated bile at a strongly acidic pH of 3.0 caused invasive squamous cell carcinoma in exposed hypopharyngeal mucosa (HM) [10,11,12]. We defined the essential antiapoptotic role of NF-κB as a mechanistic link in supporting its tumorigenic effect in vitro and in vivo [13,14,15,16,17,18,19] and that hypopharyngeal cancers harvested from patients with documented biliary esophageal reflux exclusively demonstrated highly activated NF-κB and characteristic mRNA and miRNA phenotypes vs controls similar to those described in our laboratory models [20]. Because esophageal refluxate often occurs at pH > 4.0, here we aim to determine whether weakly acidic bile is carcinogenic in vivo. We believe that due to bile content, alternative therapeutic strategies using specific inhibitors of relevant molecular pathways or receptors may be considered in patients with refractory GERD

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.